Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report [0.03%]
用于克服表皮生长因子受体突变型非小细胞肺癌中MET Y1003N介导的奥希替尼和卡马替尼联合疗法的一例报告
Molly Wilgucki,Vincent Yeung,Grace Ho et al.
Molly Wilgucki et al.
Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, is the frontline standard in the treatment of metastatic EGFR-mutant NSCLC. Although osimertinib is effective, disease progression occurs in virtually all patients, mediated by...
First-In-Human Computer-Optimized Endobronchial Ultrasound-Guided Interstitial Photodynamic Therapy for Patients With Extrabronchial or Endobronchial Obstructing Malignancies [0.03%]
用于治疗食道或气管阻塞性肿瘤的第一人种计算机优化经支气管超声引导的间质光动力疗法
Nathaniel M Ivanick,Emily R Oakley,Rajesh Kunadharaju et al.
Nathaniel M Ivanick et al.
Objective: Patients with inoperable extrabronchial or endobronchial tumors who are not candidates for curative radiotherapy have dire prognoses with no effective long-term treatment options. To reveal that our computer-op...
Screening for Brain Metastases in Patients With NSCLC: A Qualitative Study on the Psychologic Impact of Being Diagnosed With Asymptomatic Brain Metastases [0.03%]
非小细胞肺癌脑转移筛查：无症状脑转移诊断的心理学影响定性研究
Janna J A O Schoenmaekers,Jeroen Bruinsma,Claire Wolfs et al.
Janna J A O Schoenmaekers et al.
Introduction: The brain is a frequent site of metastases in NSCLC, and screening for asymptomatic brain metastases (BM) is increasingly advised in NSCLC guidelines. An asymptomatic BM diagnosis may trigger anxiety for fut...
Placing a Cancer Diagnosis in Clinical Context: Applying Functional Trajectories to Advanced NSCLC [0.03%]
临床背景下置入癌症诊断：将功能轨迹应用于晚期NSCLC患者
Heidi A Hamann,David E Gerber
Heidi A Hamann
Are We Underestimating Efficacy and Cost-Efficacy of Population Lung Cancer Computed Tomography Screening? [0.03%]
我们是否低估了肺癌筛查的疗效及成本效益？
Frederic W Grannis Jr
Frederic W Grannis Jr
Bronchorrhea, a Rare and Debilitating Symptom of Lung Cancer: Case Report and Review of the Treatment [0.03%]
支气管漏是一种罕见的肺癌症状：病例报告及治疗方法回顾
Milind Bhagat,Aditi Singh,Talal Bazzi et al.
Milind Bhagat et al.
Bronchorrhea, defined as production of voluminous watery sputum greater than 100 mL/d, is a debilitating symptom mostly found in end-stage lung cancer, specifically in invasive mucinous adenocarcinomas. Very rarely, it can primarily contrib...
Treatment of Stage I Lung Cancer Detected by Computed Tomography Screening [0.03%]
计算机断层扫描筛查发现的一期肺癌的治疗
David S Gierada,Yun Zhu Bai,Matthew B Spraker et al.
David S Gierada et al.
Introduction: Reducing lung cancer deaths through early detection by computed tomography (CT) screening requires delivery of effective treatment. We performed this retrospective study to determine the types of treatment u...
Prospective Optimization of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Lymph Node Assessment for Lung Cancer: Three Needle Agitations Are Noninferior to 10 Agitations for Adequate Tumor Cell and DNA Yield [0.03%]
支气管内超声引导下经支气管针吸活检前瞻性优化肺癌淋巴结评估：三次针筒抽吸与十次抽吸在获得足够的肿瘤细胞和DNA方面非劣效性研究
David Fielding,Andrew J Dalley,Mahendra Singh et al.
David Fielding et al.
Introduction: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS TBNA) is an important means of obtaining a tissue for advanced lung cancer. Optimizing the EBUS TBNA needling technique is important to ...
Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC [0.03%]
KRAS G12D突变型非小细胞肺癌的临床病理特征和结局
Alissa J Cooper,Alona Muzikansky,Jochen Lennerz et al.
Alissa J Cooper et al.
Introduction: Co-occurring mutations in KRAS-mutant NSCLC are associated with discrete biological properties and modulate therapeutic susceptibilities. As G12D-specific inhibitors are expected to enter the clinic, we soug...
Association of Pathologic Complete Response and Long-Term Survival Outcomes Among Patients Treated With Neoadjuvant Chemotherapy or Chemoradiotherapy for NSCLC: A Meta-Analysis [0.03%]
新辅助化疗或放疗联合化疗治疗非小细胞肺癌的病理完全缓解与长期生存结局的关系：一项系统评价和 meta 分析
Samuel Rosner,Chunnan Liu,Patrick M Forde et al.
Samuel Rosner et al.
Introduction: Increased efforts to optimize outcomes for early stage NSCLC through the investigation of novel perioperative treatment strategies are ongoing. An emerging question is the role of pathologic response and its...